The company's revenue jumped 77% in Q3 to reach $401.6 million in Q3 2024, alongside a net income of $75.6 million. It now ...
Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...
Walt Disney’s earnings beat Wall Street estimates, Super Micro Computer extends losses, and Cisco posts fiscal first-quarter ...
Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...
The tech giant said it would offer upfront, monthly pricing for customers seeking consultations and medications for five ...
Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...
Last week, Hims & Hers Health (NYSE:HIMS) dropped another mic with its latest earnings, and the numbers are mind-blowing.
Citi analyst Daniel Grosslight has maintained their neutral stance on HIMS stock, giving a Hold rating on November 6. Daniel ...